key: cord-0762005-r7nffxbz
authors: Lozano‐Rodríguez, Roberto; Terrón‐Arcos, Verónica; Montalbán‐Hernández, Karla; Casalvilla‐Dueñas, José Carlos; Bergón‐Gutierrez, Marta; Pascual‐Iglesias, Alejandro; Quiroga, Jaime Valentín; Aguirre, Luis A.; Pérez de Diego, Rebeca; Vela‐Olmo, Carmen; López‐Morejón, Lissette; Martín‐Quirós, Alejandro; del Balzo‐Castillo, Álvaro; Peinado‐Quesada, María A.; García‐Garrido, Miguel A.; Gómez‐Lage, Laura; Herrero‐Benito, Carmen; Llorente‐Fernández, Irene; Martín‐Miguel, Gema; Torrejón, Margarita; Cubillos‐Zapata, Carolina; del Fresno, Carlos; Avendaño‐Ortiz, José; López‐Collazo, Eduardo
title: Prior SARS‐CoV‐2 infection balances immune responses triggered by four EMA‐approved COVID‐19 vaccines: An observational study
date: 2022-05-11
journal: Clin Transl Med
DOI: 10.1002/ctm2.869
sha: c4980482edac4473dc0272a5a698490b81207789
doc_id: 762005
cord_uid: r7nffxbz

nan

between all vaccination regimens (Supporting information Figure S1 ). Curiously, reduced levels of anti-Spike RBD IgA at late points (>150 days after full vaccination) coincide with the neutralization capacity downregulation (Figures 2B and Supporting information Figure S1 ). Other authors have reported that in natural infection anti-Spike RBD IgA antibodies showed to be the major responsible of the neutralizing ability in early stages. 2 Regarding the cellular response, CD4 + but not CD8 + T-cell activities against SARS-CoV-2 spike peptide pool (Supporting information Figure S2A ) remained high at late-time points in naïve individuals immunized with the mRNAtype vaccines (Figures 2C and Supporting information Figure S2B ). SARS-CoV-2 spike-specific cytokines production also showed enhanced responses after vaccination with mRNA-type vaccines (Supporting information Figure  S3 ). Additionally, these antigen-specific T-cell responses were characterized by a high proportion of effector and central memory subpopulations, but with a light decrease in effector memory T cells and an increase in central memory T cells long after vaccination (Supporting information Figure S4 ). Differential responses observed in naïve individuals over time were attenuated in COVID-19-recovered subjects. We did not find patent differences in the immune responses between the four vaccination regimens in recovered individuals, neither one nor two doses of BNT162b2 or ChAdOx1 vaccines ( Figure 3 ). Besides, when comparing humoral and cellular responses between naïve and COVID-19-recovered subjects, we found higher anti-spike RBD IgG and neutralizing antibodies levels in recovered individuals, but no differences in the cellular CD4 + T-cell response were found ( Figure 4 ).

On 27 December 2020, the vaccination campaign began in Spain. One year later, this country had become one of the countries with the highest vaccination ranks, reaching a percentage of 80 of the population with a complete schedule. To date, the EMA has authorised five vaccines: ChAdOx1, Ad26.CoV2.S, mRNA-1273, BNT162b2 and NVX-CoV2373; however, the latter has not been administered in Spain. An extensive information on the prevention of hospitalization and mortality due to vaccination has been already assessed. Several studies performed in Spain confirm the impact of ratcheting up SARS-CoV-2 vaccination has had on declining COVID-19 hospitalizations and lethality rates, even though a lack of efficiency reducing the transmission rate was observed. 3, 4 Additionally, these high ranks of vaccination have supposed a reduction in the use of medical resources with a high social returns. 5 Nevertheless, a comparison between the differential immune responses triggered by each vaccine is still lacking. This is especially grievous in the case of cellular responses, since most studies solely focus on the antibody production. 6 Additionally, a medical history of COVID-19 infection has usually been an exclusion criterion in most of the reported studies.

Our findings support the use of mRNA-type vaccines for the induction of more robust humoral and cellular immune responses compared to viral-vector vaccines. Epidemiological data indicate BNT162b2 and mRNA-1273 vaccines have higher efficacy protecting against novel The comparison of Spike SARS-CoV-2-specific CD4 + proliferation in naïve and COVID-19-recovered individuals for the different vaccination strategies is shown. *p < .05; **p < .01; ***p < .001; ****p < .0001 in Kruskal-Wallis with Dunn's multiple post-hoc test and Mann-Whitney test for three or two group comparisons, respectively variants than the viral-vector ChAdOx1 and Ad26.CoV2.S vaccines. 7, 8 Additionally, previous history SARS-CoV-2, seem to have even higher efficacy. 9,10 Our findings on immune responses provide new evidence for explaining these data. A booster dose, especially in naïve individuals vaccinated with Ad26.CoV2.S or ChAdOx1, would be recommended in order to reach levels of both humoral and cellular responses similar to those observed in COVID-19recovered subjects.

Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19

IgA dominates the early neutralizing antibody response to SARS-CoV-2

Impact of scaling up SARS-CoV-2 vaccination on COVID-19 hospitalizations in Spain

On the association between COVID-19 vaccination levels and incidence and lethality rates at a regional scale in Spain

A cost-benefit analysis of COVID-19 vaccination in Catalonia. Vaccines (Basel)

Immunological mechanisms of vaccine-induced protection against COVID-19 in humans

COVID-19 vaccine effectiveness against the Omicron (B.1.1.529) variant

Comparative effectiveness of COVID-19 vaccines against the delta variant

Protection against SARS-CoV-2 after COVID-19 vaccination and previous infection

Protection against the Omicron variant from previous SARS-CoV-2 infection